| Literature DB >> 34159214 |
Wei Yu1, Yicheng Huang2, Chaoqun Ying1, Yanzi Zhou1, Li Zhang1, Jiajie Zhang2, Yingsha Chen1, Yunqing Qiu1.
Abstract
BACKGROUND: The aim of this study was to investigate the mechanism of Listeria monocytogenes (Lm) pathogenicity and resistance. In addition, the effect of existing treatment options against Lm were systematically evaluated.Entities:
Keywords: bactericidal effect; resistance mechanism; trimethoprim/sulfamethoxazole; virulent factors
Year: 2021 PMID: 34159214 PMCID: PMC8212942 DOI: 10.1093/ofid/ofab177
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Minimum Inhibitory Concentrations of 15 Antimicrobial Agents Against 6 Lm
| Antibiotics | 23949 | 26530 | 34096 | 112555 | 115423 | 117437 |
|---|---|---|---|---|---|---|
| Penicillina | 0.5 | 0.5 | 0.5 | 2 | 0.5 | 0.5 |
| Meropenema | 0.25 | 0.25 | 0.25 | 0.25 | 0.5 | 0.5 |
| Erythromycina | 0.125 | 0.125 | 0.125 | 0.25 | 0.125 | 0.125 |
| Levofloxacinb | 1 | 0.5 | 1 | 1 | 1 | 1 |
| Moxifloxacinb | 0.5 | 0.25 | 0.5 | 0.5 | 0.5 | 0.5 |
| Tetracyclineb | 0.5 | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 |
| Linezolidb | 1 | 1 | 1 | 2 | 0.5 | 1 |
| Vancomycina | 1 | 1 | 1 | 0.5 | 0.25 | 1 |
| Rifampinb | 0.03 | 0.03 | 0.03 | 0.125 | 0.125 | 0.125 |
| Daptomycinb | 8 | 8 | 8 | 8 | 8 | 8 |
| Tigecyclineb | 0.25 | 0.25 | 0.25 | 0.5 | 0.25 | 0.25 |
| Amikacinb | 2 | 2 | 2 | 2 | 2 | 8 |
| Trimethoprim-sulfamethoxazolea | 0.0625/1.1875 | 0.0625/1.1875 | 0.0625/1.1875 | 0.016/0.304 | 0.032/0.608 | 0.008/0.152 |
| Clindamycinb | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 | 2 |
Abbreviations: Lm, Listeria monocytogenes.
aBreakpoints for Lm.
bBreakpoints for Staphylococcus spp due to missing breakpoints for Lm.
Figure 1.Unrooted maximum likelihood tree of 46 clinical Listeria monocytogenes isolates from China based on multivirulence-locus sequence typing comparisons.
Figure 2.Schematic diagram of the genetic environment of the fosX and mprF gene in this study. The arrows represent the positions and direction of the elements.
Figure 3.In vitro time-kill assays using serum and cerebrospinal fluid (CSF) concentrations of meropenem, linezolid, penicillin, vancomycin, and trimethoprim/sulfamethoxazole. (a) and (d) The 5 antibiotics at serum and CSF concentrations against isolate 23949, respectively; (b) and (e) the 5 antibiotics at serum and CSF concentrations against isolate 26530, respectively; (c) and (f) the 5 antibiotics at serum and CSF concentrations against isolate 34096, respectively; (g) and (j) the 5 antibiotics at serum and CSF concentrations against isolate 112555, respectively; (h) and (k) the 5 antibiotics at serum and CSF concentrations against isolate 115423, respectively; (i) and (l) the 5 antibiotics at serum and CSF concentrations against isolate 117437, respectively. Antibiotic concentrations are denoted by different symbols. LNZ, linezolid; MEM, meropenem; PEN, penicillin; TMP/SMX, trimethoprim/sulfamethoxazole; VAN, vancomycin.